Protagonist Therapeutics Inc(PTGX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | 135.3 | EPS (ttm) | 1.04 | Insider Own | 5.39% | Shs Outstand | 64.7M | Perf Week | 4.37% |
| Market Cap | 9.08B | Forward P/E | - | EPS next Y | -108.29% | Insider Trans | -11.31% | Shs Float | 61.2M | Perf Month | -1.09% |
| Enterprise Value | 8.31B | PEG | - | EPS next Q | 2.5 | Inst Own | 114.7% | Short Float | 15.27% | Perf Quarter | 2.54% |
| Income | 0.08B | P/S | 32.2 | EPS this Y | 328.98% | Inst Trans | -4.21% | Short Ratio | 14.72 | Perf Half Y | 42.44% |
| Sales | 0.28B | P/B | 10.78 | EPS next 5Y | - | ROA | 10.34% | Short Interest | 9.35M | Perf YTD | 60.66% |
| Book/sh | 13.01 | P/C | 11.6 | EPS past 3/5Y | 7.63% -1.26% | ROE | 10.98% | 52W High | -12.74% ($160.81) | Perf Year | 87.44% |
| Cash/sh | 12.09 | P/FCF | 69.54 | Sales past 3/5Y | 20.07% 9.96% | ROIC | 9.77% | 52W Low | 90.05% ($73.83) | Perf 3Y | 887.47% |
| Dividend Est. | - | EV/EBITDA | 138.72 | EPS Y/Y TTM | 44.59% | Gross Margin | 99.45% | Volatility(W/M) | 3.67% 4.04% | Perf 5Y | 332.82% |
| Dividend TTM | - | EV/Sales | 29.46 | Sales Y/Y TTM | 34.81% | Oper. Margin | 20.69% | ATR (14) | 5.59 | Perf 10Y | 536.08% |
| Dividend Ex-Date | - | Quick Ratio | 21.71 | EPS Q/Q | 518.89% | Profit Margin | 29.4% | RSI (14) | 50.9 | Recom | 1.07 |
| Dividend Gr. 3/5Y | - | Current Ratio | 21.71 | Sales Q/Q | 3749.17% | SMA20 | 1% ($138.93) | Beta | 1.21 | Target Price | $178.2 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/8/5 | SMA50 | -2.5% ($143.92) | Rel Volume | 1.3 | Prev Close | $138.43 |
| Employees | 132 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | 3.46% 7.46% | SMA200 | 21.6% ($115.39) | Avg Volume(3M) | 0.63M | Price | $140.32 |
| IPO | 2016/8/11 | Option/Short | Yes/Yes | Trades | 6454 | Volume | 823,471 | Change | 1.37% |
🧬 A clinical- and commercialization-stage biotech company developing peptide-based new drugs. Using its proprietary peptide technology, it develops treatments for blood disorders and autoimmune diseases, and with some of its candidates advancing into collaborations with major pharmaceutical companies and regulatory approval processes, this bio-healthcare stock is building a foundation of milestone- and royalty-based revenue.
Over the past 1 year, on the higher side
13% below its 1-year high.
Traded more than usual. That is 130% of its average volume.
PTGX makes money exceptionally well
Of every $100 in sales, $20.69 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +329.0% this year.
Tap to view numbers
However, it looks expensive
Counting its debt, for $100 of yearly operating cash you would pay $13,872. Peers typically go for $4,407. Compared with its own 2-year average, it is 334% pricier now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +332.8%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership is about average
Institutions hold 114.7%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #29 of 594 in the industry
Based on market cap of $9B.
PCVX#25 Vaxcyte Inc $9B PER - 
CORT#26 Corcept Therapeutics Inc $9B PER 208.1 
KRYS#27 Krystal Biotech Inc $9B PER 39.3 
CAI#28 Caris Life Sciences Inc $9B PER 87.2 PTGX#29 Protagonist Therapeutics Inc $9B PER 135.3 
FAQ
What kind of company is PTGX?
PTGX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of PTGX?
The market cap of PTGX is approximately $9.1B, ranking 965 within its sector.
What is the P/E ratio of PTGX?
PTGX has a P/E ratio of approximately 135.3x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for PTGX?
PTGX has recorded a 52-week high of $160.81 and a low of $73.83.
